Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00717-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Wassihun Wedajo Aragaw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Folic Acid Antagonists, Mycobacterium tuberculosis, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
The Mycobacterium abscessus drug development pipeline is poorly populated, with particularly few validated target-lead couples to initiate de novo drug discovery. Trimethoprim, an inhibitor of dihydrofolate reductase (DHFR) used for the treatment of a range of bacterial infections, is not active against M. abscessus . Thus, evidence that M. abscessus DHFR is vulnerable to pharmacological intervention with a small molecule inhibitor is lacking. Here, we show that the pyrrolo-quinazoline PQD-1, previously identified as a DHFR inhibitor active against Mycobacterium tuberculosis , exerts whole cell activity against M. abscessus . Enzyme inhibition studies showed that PQD-1, in contrast to trimethoprim, is a potent inhibitor of M. abscessus DHFR and over-expression of DHFR causes resistance to PQD-1, providing biochemical and genetic evidence that DHFR is a vulnerable target and mediates PQD-1’s growth inhibitory activity in M. abscessus . As observed in M. tuberculosis , PQD-1 resistant mutations mapped to the folate pathway enzyme thymidylate synthase (TYMS) ThyA. Like trimethoprim in other bacteria, PQD-1 synergizes with the dihydropteroate synthase (DHPS) inhibitor sulfamethoxazole (SMX), offering an opportunity to exploit the successful dual inhibition of the folate pathway and develop similarly potent combinations against M. abscessus . PQD-1 is active against subspecies of M. abscessus and a panel of clinical isolates, providing epidemiological validation of the target-lead couple. Leveraging a series of PQD-1 analogs, we have demonstrated a dynamic structure-activity relationship (SAR). Collectively, the results identify M. abscessus DHFR as an attractive target and PQD-1 as a chemical starting point for the discovery of novel drugs and drug combinations that target the folate pathway in M. abscessus .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey, USA.
- Merck & Co., Inc. , West Point, Pennsylvania, USA.
- Department of Medical Sciences, Hackensack Meridian School of Medicine , Nutley, New Jersey, USA.
- Merck & Co., Inc. , Boston, Massachusetts, USA.
- MSD Animal Health Innovation GmbH, Zur Propstei , Schwabenheim, Germany.
- Department of Microbiology and Immunology, Georgetown University , Washington, USA.
ORCID-Profile: Véronique A Dartois, Thomas Dick
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Aragaw, W. W., Negatu, D. A., Bungard, C. J., Dartois, V. A., Marrouni, A. E., Nickbarg, E. B., Olsen, D. B., Warrass, R., & Dick, T. (2024). Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00717-23
Vancouver
Aragaw WW, Negatu DA, Bungard CJ, Dartois VA, Marrouni AE, Nickbarg EB, et al. Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00717-23
BibTeX
@article{Aragaw2024,
author = {Aragaw, Wassihun Wedajo and Negatu, Dereje A and Bungard, Christopher J and Dartois, Véronique A and Marrouni, Abdellatif El and Nickbarg, Elliott B and Olsen, David B and Warrass, Ralf and Dick, Thomas},
title = {Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00717-23}
}
EUVIMED